UNASSIGNED: Elevated @entity1255 concentrations are associated with a decline in physical function in elderly @entity1 . @entity1255 -lowering therapy may slow down this decline. This study aimed to examine the effect of a 2-year intervention of @entity2186 and @entity1501 supplementation on physical performance, handgrip strength, and risk of falling in elderly subjects in a double-blind, randomized placebo-controlled trial. @entity1 aged >= 65  years with elevated plasma @entity1255 concentrations [12-50    mol/L (n  =  2919)] were randomly assigned to daily supplementation of 500    g @entity2186 , 400    g @entity1501 , and 600  IU @entity3875 , or to placebo with 600  IU @entity3875 . Physical performance (range 0-12) and handgrip strength (kg) were measured at baseline and after 2  years. Falls were reported prospectively on a research calendar. Intention-to-treat (primary) and per-protocol (secondary) analyses were performed. Physical performance level and handgrip strength significantly decreased during the follow-up period, but this decline did not differ between groups. Moreover, time to first fall was not significantly different (HR: 1.0, 95  % CI 0.9-1.2). Secondary analyses on a per-protocol base identified an interaction effect with age on physical performance. In addition, the treatment was associated with higher follow-up scores on the walking test (cumulative OR: 1.3, 95  % CI 1.1-1.5). Two-year supplementation of @entity2186 and @entity1501 was neither effective in reducing the age-related decline in physical performance and handgrip strength, nor in the prevention of falling in elderly @entity1 . Despite the overall null-effect, the results provide indications for a positive effect of the intervention on gait, as well as on physical performance among compliant @entity1 >80  years. These effects should be further tested in future studies.

A Randomized Controlled Trial to Examine the Effect of 2-Year @entity2186 and XXXX Supplementation on Physical Performance, Strength, and Falling: Additional Findings from the B-PROOF Study.

@entity1 :: ('9606', 'Species') :: ['Participants', 'persons'] @entity1501 :: ('MESH:D005492', 'Chemical') :: ['folic acid'] @entity3875 :: ('MESH:D002762', 'Chemical') :: ['vitamin D3'] @entity1255 :: ('MESH:D006710', 'Chemical') :: ['homocysteine', 'Homocysteine'] @entity2186 :: ('MESH:D014805', 'Chemical') :: ['vitamin B12']
@entity1501 :: (MESH:D005492,Chemical) :: ['Folic Acid']
